Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial respon...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-02, Vol.135 (7), p.510-513
Hauptverfasser:	Strati, Paolo, Schlette, Ellen J., Solis Soto, Luisa M., Duenas, Daniela E., Sivina, Mariela, Kim, Ekaterina, Keating, Michael J., Wierda, William G., Ferrajoli, Alessandra, Kantarjian, Hagop, Estrov, Zeev, Jain, Nitin, Thompson, Philip A., Wistuba, Ignacio I., Burger, Jan A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Female Humans Letter to Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - immunology Macrophages - pathology Male Middle Aged Phenotype Pyrazoles - therapeutic use Pyrimidines - therapeutic use Remission Induction Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!